Related Experiment Video
Updated: Mar 20, 2026
Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens
Published on: August 25, 2023
Advances in molecular and genetic profiling of meningiomas for improved diagnosis, prognosis, and targeted therapy
1Department of Radiation Oncology, PSG Institute of Oncology, PSG Institute of Medical Sciences and Research, Coimbatore, Tamil Nadu, India.
Background:
Meningiomas exhibit substantial biological and clinical heterogeneity, and traditional histopathology alone often fails to accurately predict tumor behavior. Advances in molecular and genetic profiling have significantly enhanced diagnostic precision, prognostic assessment, and therapeutic decision-making.
Methods:
This review synthesizes current evidence on genomic, epigenomic, transcriptomic, and liquid biopsy-based approaches used to characterize meningiomas.
Results:
Key developments include characterization of NF2 and non-NF2 driver mutations, refinement of DNA methylation-based classification systems, identification of high-risk markers such as TERT promoter mutations and CDKN2A/B deletions, and the emergence of targeted therapeutic strategies. Liquid biopsy and circulating biomarkers further enable non-invasive disease monitoring and molecular risk stratification.
Conclusion:
Molecular profiling has transformed meningioma classification and risk prediction, supporting a shift toward precision neuro-oncology. Future progress will depend on integrated multi-omic diagnostics, improved biomarker-guided surveillance, and development of targeted therapeutic options for aggressive molecular subgroups.
